Clinical Trial

A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

Study acronym: ALL-TARGET
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the benefit of a precision medicine based strategy (targeted therapeutic options (TTOs)) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (in terms of composite remission).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-04.
Trial Details
NCT Number NCT07522801
Lead Sponsor Philippe ROUSSELOT
Conditions LAL
Enrollment 93 participants
Start Date 2026-09-01
Primary Completion 2029-12-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-17